BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately ...

Lecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial ...

Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...

Discover key insights from Biogen's Q1 2025 earnings call, highlighting LEQEMBI's growth, product launches, and a strong pipeline driving ...

The drop in GPM is likely due to the increasing proportion of sales from Leqembi, one of Eisai’s products. The company’s guidance for current-year sales of ¥790 billion, which is the same as last year ...

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take ...

Eisai Europe and Biogen Idec have announced the validation of a Marketing Authorisation Variation by the Medicines and Healthcare products Regulatory Agency (MHRA) for lecanemab – marketed as Leqembi® ...